In the Swedish real-world study described in the Alzheimer's Association AAIC primary-care release, primary-care accuracy rose from 65% before blood results to 93% after. For younger-onset families, this gives a symptomatic adult aged 40 or older a clear follow-up path, not a final diagnosis. PrecivityAD2 is a blood test that measures amyloid-beta and phosphorylated tau proteins tied to Alzheimer's pathology alongside clinical assessment. A primary-care result helps sort whether Alzheimer's is likely, unlikely, or needs confirmatory testing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the primary-care study showed
- Why ruling out matters most
- What age 40 and older changes for younger-onset families
- Which questions to ask about a result
What the primary-care study showed
The Lund University-led study enrolled 1,310 patients with mild cognitive impairment or dementia and 165 physicians, according to the Alzheimer's Association. Physicians made a diagnosis before the blood result, then again after seeing it.
After results, physicians changed the diagnosis in about one-third of patients. They also changed planned care, exams, or management in more than half. That shift matters for families because the first clinical impression often changes once biology is measured.
Why ruling out matters most
For primary-care physicians the test was especially useful for ruling out Alzheimer's disease rather than ruling it in alone, the Association reported. A low-risk blood result can redirect attention toward sleep disorders, mood disorders, thyroid disease, medication effects, or other brain disorders.
A high-risk result does not stand alone. Alzheimer's Association guidance allows sensitive triage tests to rule out disease but requires a positive result to be confirmed by spinal-fluid testing or amyloid PET. Families should treat a positive as a prompt for referral and confirmation.
What age 40 and older changes for younger-onset families
C2N Diagnostics' PrecivityAD2 received FDA clearance on Aug. 20, 2026 as the first Alzheimer's blood test indicated for symptomatic adults aged 40 and older, according to the C2N Diagnostics announcement. That indication fits younger-onset concerns, where symptoms may start in the 40s or 50s.
Clearance does not replace standard workup. Use remains tied to history, cognitive testing, neurologic exam, labs, and brain imaging when needed. A blood result enters that workup, then helps decide about specialist referral and confirmatory testing.
Which questions to ask about a result
Bring the result, symptom timeline, medications, and family history to the visit. Ask for plain-language meaning of the risk score and what else could explain symptoms.
These follow-up steps reflect the Association's clinical practice guideline, which calls for comprehensive evaluation first and confirmation of positive blood results. Ask the office to record the plan for confirmation, referral, and symptom monitoring before you leave.
- Do we need confirmatory PET or spinal-fluid testing?
- Do we need referral to a memory specialist?
- What other causes have we ruled out?
- Could a clinical trial fit if Alzheimer's is confirmed?
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Changed and What Comes Next for Primary Care Patients
- Strengths-Based Dementia Care in the 2026 NIA Report: What Changed and What Comes Next for Spouses and Partners
- The 2026 Alzheimer’s Caregiving Burden: Questions Families Can Ask Locally
